SANA
Sana Biotechnology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 3 ▲ Sana Biotechnology reported Q4 and full-year 2025 financial results…
- Mar 13 ▲ Sana Biotechnology announced 14-month data from a first-in-human stu…
- Mar 13 FDA: Sana Biotechnology Announces Continued Positive Clinical R…
- Apr 13 ▲ Sana Biotechnology entered into a stock purchase agreement with Mayo…
- Apr 13 ▲ Sana Biotechnology announced a strategic collaboration with Mayo Cli…
- Apr 13 Contract: Sana Biotechnology and Mayo Clinic Announce Strategic Coll…
- May 11 ▼ Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share…
- Jul 13 FDA: Sana Biotechnology Announces Follow-On Publication in The…
- Nov 5 ▲ Earnings: SANA Q3 2026 Earnings: EPS $-0.14 (+7.4% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 17 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
13 of 15 rate it Buy or better.
- Short sellersSTEADY
Short interest −0.6% to 40.60M shares. 15.8 days to cover, ≈13.6% of shares.
- TrendDOWNTREND
30% below its 50-day average. New closing low $1.88 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | DOUBLED | $8.8M |
| Quadrature Capital Ltd | DOUBLED | $885.5K |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $719.0K |
| Squarepoint Ops LLC | DOUBLED | $688.0K |
| VANGUARD ASSET MANAGEMENT, Ltd | ADD | $410.1K |
| CITIGROUP INC | TRIM | $373.2K |
| BARCLAYS PLC | DOUBLED | $351.7K |
| Creative Planning | ADD | $231.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Aug 14, 2026 | B of A Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Bishop Hans Edgar Director Oct 5, 2026 | AWARD | 8,680 sh |
PATEL DHAVALKUMAR DHIRAJLAL EVP, Chief Scientific Officer Aug 27, 2026 | TAX W/H | $169.2K |
PATEL DHAVALKUMAR DHIRAJLAL EVP, Chief Scientific Officer Aug 26, 2026 | EXERCISE | 125,000 sh |
Bishop Hans Edgar Director Jul 6, 2026 | AWARD | 6,297 sh |
NELSEN ROBERT Director Jun 4, 2026 | AWARD | 90,000 sh |
Bishop Hans Edgar Director Jun 4, 2026 | AWARD | 90,000 sh |
Bilenker Joshua H. Director Jun 4, 2026 | AWARD | 90,000 sh |
REICIN ALISE Director Jun 4, 2026 | AWARD | 90,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 3 press releases · 1 bullish · 1 bearish · 7 neutral- NEUTRAL 8-KNov 5, 2026
Sana Biotechnology reported Q3 2026 GAAP net income of $20.4 million ($0.07 per share), driven by…
The GAAP net income is entirely driven by a non-cash fair value adjustment from the Cobalt amendment, not operational improvement. Monitor the SC451 IND filing and SG293 clinical data in 2027 as key…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 37,293,854…
No change in Fidelity's passive stance; the filing is a routine periodic update. Monitor for any future conversion to a 13D filing, which would signal activist intent.
- NEUTRAL 8-KAug 10, 2026
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), a narrower loss vs…
The modest EPS miss is noise for a pre-revenue biotech; the stock will move on SC451 IND filing and SG293 clinical data catalysts expected within 6-9 months. Monitor for IND submission announcements…
- NEUTRAL PRESS-RELEASEAug 10, 2026
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than…
Monitor for SC451 IND filing and SG293 initial clinical data later this year, as these are the key near-term catalysts. The $160.5M cash position provides runway into mid-2027, but the ATM program…
All SANA filing & press-release reports (12)
- 8-K reportNov 5, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportMay 11, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportApr 24, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- PRESS-RELEASE reportMar 13, 2026
- PRESS-RELEASE reportMar 3, 2026